Journal: BioMed Research International

Article Title: H-CRRETAWAC-OH, a Lead Structure for the Development of Radiotracer Targeting Integrin α 5 β 1 ?

doi: 10.1155/2014/243185

Figure Lengend Snippet: FACS analysis of human prostate carcinoma DU145 as well as human melanoma M21 and M21-L cells. (a): (A) + (B): DU145; (C) + (D): M21; (E) + (F): M21-L; (A), (C), (E): IgG-isotype overlay with α 5 β 1 ; (B), (D), (F): IgG-isotype overlay with α v β 3 ; (b): presentation of the median of the different analysis.

Article Snippet: Cells were washed with cold PBS and incubated with mouse anti-human integrin α 5 β 1 (MAB 1999, Millipore, 1 : 75), mouse anti-human integrin α v β 3 (MAB1976, clone LM609, Millipore, 1 : 75), or a negative control IgG (DAKO) for 30 minutes at 4°C, followed by incubation with a FITC-labelled goat anti-mouse secondary antibody (1 : 400, 2.5 μ L in 1 mL DAKO).

Techniques:

Journal: Journal of Oncology

Article Title: Anoikis Resistance as a Further Trait of Acidic-Adapted Melanoma Cells

doi: 10.1155/2019/8340926

Figure Lengend Snippet: An anoikis resistant-like phenotype in acidic melanoma cells. (a) Representative images of western blot for N-cad, EGFR, pAKT/AKT, pERK/ERK, Tie1, IKB, and β -actin of A375M6 melanoma cells exposed to standard medium (pH 7.4), to an acidified medium for 24 hours (transient exposure, pH 6.7) or to a reduced pH medium, for approximately three months (chronic exposure, pH 6.7c), and (right) densitometry graph of protein expression. (b) Representative images (left) of invasiveness of melanoma cells grown in different pH conditions in the presence or absence of 25 μ M Ilomastat (a metalloproteinases inhibitor) and quantitative analysis (right) of the number of cells that migrated through Matrigel. (c) Representative images (left) of flow cytometric analysis of α v β 3 and of α v β 5 integrin expression of A375M6 melanoma cells grown in different pH conditions and (right) quantitative analysis of integrin expression as percentage of increment in Mean Fluorescent Intensity. Each experiment was conducted in triplicate and data are expressed as mean ± SEM of at least three independent experiments. ∗ p<0.05.

Article Snippet: Mouse anti-human integrin receptor α v β 3 (clone LM609, Millipore) and mouse anti-human integrin receptor α v β 5 (sc13588, Sigma), mouse monoclonal AF6-88.5.3 specific for class I H-2Kb antigen (provided by Dr. S. Gattoni-Celli, Medical University of South Carolina, USA) (Calorini 1999) or mouse monoclonal HLA-ABC antigen clone W6/32 (DAKO), were used.

Techniques: Western Blot, Expressing

Journal: PLoS ONE

Article Title: Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice

doi: 10.1371/journal.pone.0147173

Figure Lengend Snippet: Cells were grown and immunostained with CAR, integrin α v β 3 , or α v β 5 antibody and then subjected to flow cytometric analysis. Columns, percentages of cells expressing CAR, αvβ3 and αvβ5. Data are presented as means ± standard deviation for three independent experiments.

Article Snippet: To detect expression of CAR and integrin α v β 3 and α v β 5 , the cells were detached using an enzyme-free dissociation solution and then incubated with a mouse monoclonal anti-human CAR antibody (Upstate Biotechnology, Lake Placid, NY, USA), a mouse monoclonal anti-human integrin α v β 3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or a mouse monoclonal anti-human integrin α v β 5 antibody (R&D Systems, Inc., Minneapolis, MN, USA), all at a dilution of 1:100 for 1 h on ice.

Techniques: Expressing, Standard Deviation

Journal: Theranostics

Article Title: Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters

doi: 10.7150/thno.13917

Figure Lengend Snippet: 18 F-Alfatide II MicroPET/CT imaging of U87MG tumor-bearing mice, IHC staining for integrin α v β 3 of tumor tissues and the relevant quantitative and correlation analysis. (A) Representative MicroPET/CT images at 1.0 h after intravenous injection of 18 F-Alfatide II (5.55 MBq per mouse) on days 0, 1, 3, 7 and 13 post treatment. (B, C) Quantitative %ID/g max of tumor uptake and the ratios of tumor to contralateral muscle (T/M) in the sunitinib and control groups based on ROIs analysis from 18 F-Alfatide II MicroPET/CT. (D, E) IHC and quantitative analysis of tumor sections about integrin α v β 3 . (F) Correlations between 18 F-Alfatide II T/M and integrin α v β 3 expression of tumor. Notes: The tumors were indicated by arrows. ** P < 0.01, within the sunitinib group, compared to day 0. # P < 0.05, # # P < 0.01, between the sunitinib group and the control group.

Article Snippet: The sections were incubated with mouse anti-human integrin α v β 3 antibody (1:100, R&D) for 2 h and subsequently visualized with dye-conjugated donkey anti-mouse secondary antibody (1:200, Abcam).

Techniques: Imaging, Immunohistochemistry, Injection, Control, Expressing